On Friday, Universal Insurance Holdings, Inc (NYSE:UVE)’s shares declined -3.67% to $24.65.
On April 13, Universal Insurance Holdings, declared that its Board of Directors declared a cash dividend of $0.12 per share of common stock to be paid on July 2, 2015 to shareholders of record on June 18, 2015. If declared and paid as intended, the annual aggregate dividend in 2015 will be $0.48 for each common share.
The declaration and payment of future dividends is subject to the Board’s discretion and will be dependent upon future earnings, cash flows, financial requirements, and other factors.
Universal Insurance Holdings, Inc., through its auxiliaries, provides various property and casualty insurance products. The company primarily underwrites homeowners insurance products; and offers reinsurance intermediary brokerage services. It offers its products through a network of independent agents in Delaware, Florida, Georgia, Hawaii, Indiana, Maryland, Massachusetts, North Carolina, Pennsylvania, and South Carolina, the United States.
Forum Energy Technologies Inc (NYSE:FET)’s shares dropped -3.65% to $21.37, during the last trading session on Friday.
On April 1, Forum Energy Technologies Inc. declared that it will host its first quarter 2015 earnings conference call at 9:00 AM CDT on Friday, April 24, 2015. Forum will issue a press release regarding its first quarter 2015 earnings prior to the conference call.
Forum Energy Technologies, Inc. designs, manufactures, and distributes products to the oil and natural gas industry in the United States and internationally. The company operates in two segments, Drilling & Subsea, and Production & Infrastructure. The Drilling & Subsea segment designs and manufactures products, and provides related services to the subsea construction, drilling, well construction, completion, and intervention markets.
At the end of Friday’s trade, Celladon Corp (NASDAQ:CLDN)‘s shares dipped -3.64% to $16.52.
Formerly on March 30, Celladon Corp. declared financial results for the quarter and year ended December 31, 2014 and recent corporate highlights.
“In the last year, Celladon has made noteworthyprogress in our clinical programs and pre-commercial planning for MYDICAR, counting preparations for commercial manufacturing and other long lead-time activities. Our CUPID2 trial is evaluating the use of MYDICAR to treat systolic heart failure, known as HFrEF, and we received Breakthrough Therapy designation for this program from the FDA in April of last year. The CUPID2 trial is proceeding according to plan and we look forward to un-blinding and announcing top-line data from this trial in late April 2015. Following last year’s financing activities, we are well positioned to advance our pipeline and development initiatives in 2015,” said Krisztina Zsebo, Ph.D., Chief Executive Officer of Celladon.
Fourth Quarter 2014 and Recent Corporate Highlights
MYDICAR(R)
- In February 2015, we reached the last subject’s last visit during the 12 month primary data analysis period in the CUPID2 study, thereby reaching the study’s primary analysis data cutoff. We remain on track to un-blind the data and declare top-line results from this study in late April 2015.
- In December 2014, we commenced work with Novasep, Inc. (Novasep) for the potential future commercial manufacture of MYDICAR drug substance (AAV1/SERCA2a), and in March 2015, we declared the execution of a development, manufacturing and supply contract with Novasep, which, if supported by the CUPID2 data, positions the parties to continue with the process transfer, facility retrofitting, development and manufacturing activities necessary for the future commercial supply of MYDICAR drug substance. If we proceed with the ongoing activities beyond a specified termination period following the un-blinding of CUPID2, we would commit to a multi-year contract for the future commercial supply of MYDICAR drug substance.
- In November 2014, we declared the execution of a facility construction and commercial supply contract with Lonza Biologics, Inc. (Lonza). In exchange for a reservation fee, we have the option, exercisable during a specified timeframe and with further financial obligation, to have Lonza commence construction of a new commercial viral therapeutics manufacturing facility, the exercise of which would commit us to a multi-year contract for the future commercial supply of MYDICAR drug substance.
- In December 2014, we conducted initial scale up of our MYDICAR (AAV1/SERCA2a) viral manufacturing process to 2,000 liter commercial scale, concluding the first demonstration batch at Lonza’s Houston facility.
Celladon Corporation, a clinical-stage biotechnology company, focuses on developing cardiovascular gene therapy and calcium dysregulation. The companys lead product candidate comprises MYDICAR that uses genetic enzyme replacement therapy to correct the Sarco/endoplasmic reticulum Ca 2+ -ATPase 2a enzyme deficiency in heart failure patients that result in inadequate pumping of the heart. Its MYDICAR product is used to treat patients with systolic heart failure, diastolic heart failure, and advanced heart failure, in addition to to treat pulmonary arterial hypertension and arteriovenous fistula maturation failure.
Check Point Software Technologies Ltd (NASDAQ:CHKP), ended its Friday’s trading session with -3.55% loss, and closed at $81.75.
On April 15, Check Point Software Technologies Ltd. declared the company leads the worldwide market share for Firewall Equipment in Q4 2014 and FY 2014, according to research published by Gartner1.
Gartner’s Market Share Enterprise Network Equipment research states:
- Check Point leads worldwide market share with 23% of the Firewall Equipment market in Q4 2014.
- Check Point’s number one market share position represents an 8.2 and 10.9 percentage point lead over the two nearest competitors ranked in the Firewall Equipment market in Q4 2014.
- Check Point leads worldwide market share with 22.7% of the Firewall Equipment market in FY 2014.
- Check Point’s number one market share position represents a 6.8 and 11.2 percentage point lead over the two nearest competitors ranked in the Firewall Equipment market in FY 2014.
Check Point Software Technologies Ltd. develops, markets, and supports a range of software, combined hardware, and software products and services for information technology (IT) security worldwide.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
